- Entry
- —
- Now
- $0.8699
- Target
- —
- Score
- —
Up to 84% of GLP-1 induced weight loss retained with Revita® versus 46% with sham at one year in patients receiving complete duodenal ablations Next anticipated Revita® milestones are topline six-month randomized data from the REMAIN-1 Pivotal Cohort in early Q4 2026 and a potential FDA De Novo marketing application submission in late Q4 2026 Company to host investor webcast today at 8:00 a.m. ET. Quite excited to see what they have to say. Link to 8-K: [SEC Filing | …
— ORIGINAL POST ·
Fractyl Health (GUTS) Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation
· r/pennystocks
· Jul 15, 2026